United States · Wires & real time · PR Newswire

Paradigm Therapeutics, Inc. annonce l'inscription du premier patient dans un essai de phase 3 pour le SD-101 (Zorblesia™) dans l'épidermolyse bulleuse

Published by PR Newswire · United States 2 h ago

Le SD-101 (Zorblesia™) est le premier traitement topique développé pour traiter les plaies et les lésions sur toute la surface de la peau chez les patients atteints des trois…

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading

Associated Press (Business)

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

Business Wire

Lyric Releases Framework for Measuring Healthcare Decision Intelligence Maturity in Payment Accuracy

Dow Jones Newswires

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires